Tevogen Bio Holdings Inc

For the period ended Dec 31, 2023. Filed Apr 29, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 29, 2024

TVGN$5.84+4.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Changes in Shareholders’ Deficit

FOR THE YEAR ENDED DECEMBER 31, 2023

	Ordinary shares
Class A (Non-redeemable) · Class B
	Shares	Amount	Shares	Amount	Additional Paid-in Capital	Accumulated Deficit	Total Shareholder’s Deficit
Balance, December 31, 2022	1,450,000	$145	11,983,333	$1,198	$—	$(14,784,691)	$(14,783,348)
Conversion of Class B shares	11,983,333	1,198	(11,983,333)	(1,198)	—	—	—
Proceeds allocated to Class A shares issuable from the note payable	—	—	—	—	275,306	—	275,306
Accretion of carrying value to redemption value	—	—	—	—	(275,306)	(2,526,621)	(2,801,927)
Net loss	—	—	—	—	—	(67,325)	(67,325)
Balance, December 31, 2023	13,433,333	$1,343	—	$—	$—	$(17,378,637)	$(17,377,294)

FOR THE YEAR ENDED DECEMBER 31, 2022

	Ordinary shares
Class A · Class B
	Shares	Amount	Shares	Amount	Additional Paid-in Capital	Accumulated Deficit	Total Shareholder’s Deficit
Balance, December 31, 2021	1,450,000	$145	11,983,333	$1,198	—	$(14,229,052)	$(14,227,709)
Accretion of carrying value to redemption value	—	—	—	—	—	(4,964,000)	(4,964,000)
Net income	—	—	—	—	—	4,408,361	4,408,361
Balance, December 31, 2022	1,450,000	$145	11,983,333	$1,198	$—	$(14,784,691)	$(14,783,348)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.